For the Third Consecutive Year, Implant Sciences' QS-B220 Wins the 2015 GSN Homeland Security Award for "Best Explosive Detection Product or Solution"

Nov 19, 2015, 09:00 ET from Implant Sciences Corporation

WILMINGTON, Mass., Nov. 19, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, announced that its QS-B220 desktop explosives and drugs trace detector has won the 2015 GSN Homeland Security Award for " Best Explosive Detection Product or Solution" for the third year in a row. The QS-B220 also won the GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint" in June 2015.

The GSN Homeland Security Awards are sponsored by Government Security News, a leading publisher of government and homeland security news. The GSN 2015 Homeland Security Awards Program was organized to honor the distinguished vendors of IT Security and Physical Security products and solutions and the dedicated federal, state, county and municipal government agencies, whose combined efforts keep our nation secure. Now in its 7th year, the GSN Homeland Security Awards Program is widely considered to be one of the most prestigious awards programs covering the broad Homeland Security field.

"As the saying goes, security has to be right 100% of the time and terrorists only have to be right once. Implant Sciences prides itself in having superior detection performance with the lowest False Alarm Rate (FAR) in the industry," stated Robert Liscouski, President of Implant Sciences. "We are honored to have been selected by GSN, once again, for the GSN Homeland Security Awards."

"Implant Sciences has had an incredible year, with its leading technology being adopted all around the world by the highest profile customers. Being selected as the "Best Explosive Detection Product of Solution" by GSN for the third year in a row is another sign that our trace detection technology has been recognized as the new standard in the market," added Dr. Darryl Jones, Executive Vice President of Implant Sciences.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint."  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; the risk that the Company may not be able to meet demand for its products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.


Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116  

SOURCE Implant Sciences Corporation